CF
PRLD icon

Corebridge Financial’s Prelude Therapeutics PRLD Stock Holding History

Corebridge Financial’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,458
Closed -$4.96K – 2090
2025
Q1 		$4.96K Sell
6,458
-96
-1% -$90 ﹤0.01% 2999
2024
Q4 		$8.36K Sell
6,554
-495
-7% -$657 ﹤0.01% 3012
2024
Q3 		$14.6K Sell
7,049
-43
-0.6% -$199 ﹤0.01% 2998
2024
Q2 		$27K Buy
+7,092
New +$28.9K ﹤0.01% 2967

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Corebridge Financial's PRLD Position: Q2 2025 in Review

Corebridge Financial sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 6,458 shares — an estimated $4.96K sold.

Corebridge Financial first reported a position in PRLD in Q2 2024 and held it in 4 quarters. The position peaked at $27K in Q2 2024. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

  • Corebridge Financial reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 6,458 Prelude Therapeutics shares in Q2 2025, an estimated $4.96K.
  • Corebridge Financial first reported a position in Prelude Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Prelude Therapeutics position peaked at $27K in Q2 2024.
  • 50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.